生产企业：Umecrine Cognition AB
Golexanolone is a first-in-class GABAA receptor-modulating steroid antagonist (GRAS) developed by Umecrine Cognition AB for the treatment of fatigue and cognitive symptoms associated with chronic liver disease. It is currently in Phase 1b/2a clinical development for primary biliary cholangitis (PBC)-related fatigue, with results expected in H2 2026.
Golexanolone is a first-in-class GABAA receptor-modulating steroid antagonist (GRAS) developed by Umecrine Cognition AB for the treatment of fatigue and cognitive symptoms associated with chronic liver disease. It is currently in Phase 1b/2a clinical development for primary biliary cholangitis (PBC)-related fatigue, with results expected in H2 2026.
Golexanolone is a GABAA receptor-modulating steroid antagonist (GRAS) that acts directly on the central nervous system to normalize brain signaling impaired by chronic neuroinflammation. It belongs to a new class of drugs targeting CNS symptoms arising from chronic liver disease and potentially neurodegenerative conditions.
Golexanolone is being developed for the treatment of central nervous system-driven fatigue and cognitive impairment in patients with primary biliary cholangitis (PBC). It has also been studied in hepatic encephalopathy, where it demonstrated improvements in cognition and alertness.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
